Compare AbbVie Inc (ABBV) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Cenovus Energy Inc — how do they compare? AbbVie Inc trades at $253.61 (market cap $449.91B), while Cenovus Energy Inc trades at $26.58 (market cap $47.02B). The key difference: AbbVie Inc is far larger — about 9.6× Cenovus Energy Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | CVE | |
|---|---|---|
Market Cap | $449.91B | $47.02B |
Sector | Health | Energy |
52-Week High | $261.07 | $31.80 |
52-Week Low | $184.85 | $13.96 |
Enterprise Value | $513.38B | $54.90B |
Dividend Yield | 2.72% | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Cenovus Energy (CVE) trades at $25.21, up 2.27% with a bearish technical signal. Recent earnings beats and an attractive P/E of 13.78 highlight fundamental strength, while cash flow trends show operational resilience despite negative net flows. The company maintains a solid balance sheet with a debt-to-asset ratio of 13.63% as of 2024.
CVE offers value with low valuation multiples and consistent profitability, but faces headwinds from volatile oil prices and regulatory challenges. Analyst consensus is mixed with 40.74% buy ratings, suggesting cautious optimism for long-term growth amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
